Nanologix (A0EQWW) - Fakten & Meinungen - 500 Beiträge pro Seite

[Gurkensaft]

Company Update aus 2012:
http://nanologix.com/news/2011_company_update.html

Beide Publikationen zu GBS & TB sind nun veröffentlicht

[Gurkensaft]

Accuracy of an Accelerated, Culture-Based Assay for Detection of Group B Streptococcus

Infectious Diseases in Obstetrics and Gynecology
Volume 2013 (2013), Article ID 367935, 4 pages

http://www.hindawi.com/journals/idog/2013/367935/

[Gurkensaft]

NanoLogix Rapid TB Detection Results Published In Journal of Microbial & Biochemical Technology

Major Third-party R&D lab achieves 5-day Tuberculosis detection, compared to weeks for standard tests

Hubbard, OH -December 17, 2012 -- NanoLogix (OTC Markets: NNLX) An independent third-party study by one of the foremost Biomedical Research centers in the U.S has demonstrated that NanoLogix's BioNanoPore (BNP) Ultra-Fast Identification Technology enables detection of live Tuberculosis cultures in five days as opposed to two+ weeks with traditional methods.

The peer reviewed study appears in the online edition of the Journal of Microbial & Biochemical Technology.

http://www.omicsonline.org/1948-5948/pdfdownload.php?downloa…

[Gurkensaft]

http://www.uthouston.edu/media/story.htm?id=e3142cc6-bc5b-41…

UTHealth researchers say more rapid test for Group B strep successful

HOUSTON – (March 8, 2013) – A more rapid laboratory test for pregnant women to detect potentially deadly Group B strep (GBS) has been successful at identifying GBS colonization in six and a half hours, according to the results of a study from The University of Texas Health Science Center at Houston (UTHealth).

The more rapid test could be helpful for the 13 percent of patients who experience pre-term labor before they are screened for GBS, which usually occurs between 35 and 37 weeks of gestation. The current standard test takes 48 hours. Antibiotics can be administered at the time of delivery to kill the bacteria.

“This new test could change the management of patients who present to labor and delivery with threatened preterm labor and aren’t expected to deliver right away,” said Jonathan Faro, M.D., Ph.D., assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Medical School at Houston, part of UTHealth. “It would likely gain use in this patient population, which is a small number, but still very significant clinically. We could target this population and this would help cut down on overuse of resources and minimize our contribution to the increased level of bacterial resistance.”

The new test, developed by NanoLogix, can also detect antibiotic sensitivities for women who are allergic to penicillin, saving the additional 48 hours the standard test for antibiotic sensitivity takes, Faro said.

GBS is the most common cause of sepsis (blood infection) and meningitis and a frequent cause of pneumonia in newborns, according to the Centers for Disease Control (CDC). The CDC estimates the bacterium, which is passed from mother to child through the birth canal, is carried by 25 to 30 percent of women at any one time. Because GBS has few symptoms, many women do not know they are carriers. In 2001, 1,700 babies less than 1 week old contracted GBS, which can lead to disability and death.

In the study, 356 patients at 35 to 37 weeks of gestation at UT Physicians clinics were tested for GBS using two standard tests and the new test, which provided a high level of validity according to the study results.

Faro is studying an even faster version of the test with the hope it could detect GBS in as little as 30 minutes. That could make a difference for the up to 15 percent of pregnant women who arrive for full-term delivery and have not been screened. Right now, obstetricians must determine whether to give these women intravenous antibiotics automatically or use risk factors, which have been shown to be only half as effective as laboratory tests, to assess whether the patient has the bacteria.

“Typically, if a patient comes into the emergency room in labor and you don’t know if she carries GBS, you have to treat her with antibiotics,” Faro said. “Everyone is concerned that the overuse of antibiotics is leading to greater resistance to them. Some have expressed concern that by giving penicillin to everyone, we are increasing the number of babies who are getting sick from E. coli sepsis.”

The study was published in a recent online edition of “Infectious Diseases in Obstetrics and Gynecology” and presented at the 33rd annual Society of Maternal Fetal Medicine meeting last month.

UTHealth co-authors include Sebastian Faro, M.D., the Dr. John T. Armstrong Professor in Obstetrics and Gynecology; Allan Katz, M.D., the Robert K. Creasy Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences; Karen Bishop, clinical trial program manager; Gerald Riddle, research associate; and Mark Turrentine, research collaborator.

[Gurkensaft]

INSERTING and REPLACING University of Texas Health Science Center at Houston Releases News of Successful NanoLogix Test

UTHealth researchers say more rapid test for Group B strep successful

HUBBARD, Ohio

Please also embed with the URL: http://www.hindawi.com/journals/idog/2013/367935/
The corrected release reads:

UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON RELEASES NEWS OF SUCCESSFUL NANOLOGIX TEST

UTHealth researchers say more rapid test for Group B strep successful
NanoLogix Inc. (NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria, announces that final results of a 14 month study done by researchers at UTHSC-Houston have been published in a recent online edition of “Infectious Diseases in Obstetrics and Gynecology.” The results were also presented at the 33rd annual Society of Maternal Fetal Medicine meeting last month in San Francisco. Researchers tested 356 pregnant patients for Group B Strep using NanoLogix BNF tests during the study, with NanoLogix test results obtained in 6.5 hours as opposed to 48 hours with standard tests.
Jonathan Faro, MD, PhD, the chief researcher on the study and assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at The University of Texas Medical School at Houston, part of UTHealth, stated: “We're very happy at UT to have the recent clinical study on GBS showing positive results with the 6.5 hour test. Even more exciting, however, is that we are now seeing results as fast as 30 minutes. This more rapid test is based on a modification of the 6.5 hour test, and has the potential to allow for antibiotic susceptibility testing in an amount of time that would have previously been considered simply impossible. The studies with GBS have been applied to other bacteria, and we are very pleased to see similar results with gonorrhea, which has been implicated last year as a multi-drug resistant pathogen. We are in the final stages of formalizing the 30 minute test for GBS, and will continue to work on additional applications for this assay.”
The news from UTHealth Houston can be found here: http://www.uthouston.edu/media/story.htm?id=e3142cc6-bc5b-41…
NanoLogix exhibited at the ASM BioDefense and Emerging Diseases Research Meeting in Washington DC 25-27 February 2013. There was strong interest in the Company’s technologies at the exhibition. Interested parties included Federal agencies, universities, large and small laboratories, NGO’s, and corporations, with resulting sales begun this week.
NanoLogix has contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders and executives in multiple health and food sectors. The specialist team is composed of current or former directors and managers of various national and international health sector corporations. This event marks the transition of the Company from a primary focus on research and development to one of marketing and production. There will be a continued science emphasis upon water quality test development with the US EPA and also product QA/QC. This new focus will also result in a reallocation of resources with a heavy focus upon increased marketing on multiple fronts.

[Gurkensaft]

April 02, 2013:
NanoLogix has been informed that they have been granted a patent in Japan for the Company's BNP detection technology. This is the first granted patent of seven patents pending for BNP throughout the world.

[Gurkensaft]

April 05, 2013:
NanoLogix plans to begin marketing this summer of their new N-Assay Multiwell Diagnostic test. The N-Assay is a machine-readable test that will be available in an assortment of size configurations for detection and identification of a variety of bacteria. Tests to date have provided consistent results in as little as 30 minutes with both high sensitivity and specificity.

[Gurkensaft]

NNLX provides company update

Company Update
The past fifteen months have been highly successful for NanoLogix as it continues to develop new products and new markets. In that time, the company has advanced in a number of important areas, including development of new technologies, increasing sales and customer bases, and garnering substantial recognition in published research on NanoLogix products and techniques. We are excited by these developments and by additional new opportunities.

New Technologies
The technological developments at NanoLogix are revolutionary. Besides improving on existing BNP and BNF products and protocols, the Company has gained great success in the market for its Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas charged FlatPacks. The FlatPack technology – exclusively licensed by NanoLogix – represents a major breakthrough in supply-chain management for these products. Users of FlatPack-packaged Petri dishes can potentially achieve significant cost savings and supply chain efficiencies over traditional Petri dish supply because select-media FlatPack plates do not require refrigeration, have a significantly reduced rate of loss in shipment and storage, and have a shelf life far beyond that of traditional Petri dishes. The company is currently selling Extended-Life Petri dishes and BNP diagnostic kits that are vacuum-packed in gas-charged FlatPacks and made in various common nutrient media configurations. Customers to date include independent laboratories and hospital laboratories, defense contractors and Federal agencies. NanoLogix products are at present being used on six classified Federal government projects, with expanded use expected this year. Those projects are funded by the United States Department of Defense and the Environmental Protection Agency.

In the past year we and our collaborators in research and development have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multiwell machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications to date are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, but not in other areas or regions that are less developed.

Scholarship and Research on NanoLogix Technologies
In December 2012 a paper was published in the Journal of Microbial and BioChemical Technology detailing preliminary results using the company’s BNP technology for detection of live Tuberculosis through culture. Those results were obtained in five days, compared to weeks with standard culture methods. http://www.omicsonline.org/1948-5948/pdfdownload.php?downloa… In January of 2013 the final results of a 356 patient clinical study by researchers at the University of Texas Health Science Center at Houston were published in the Journal of Infectious Diseases in Obstetrics and Gynecology detailing the results obtained with NanoLogix’s BNF technology for rapid detection of Group B Streptococcus in pregnant patients.http://www.hindawi.com/journals/idog/2013/367935/

New License and Patents
The company has been recently granted a patent for its BNP technology in Japan, its BNC technology in China, and has indications that it will soon receive a grant of patent in the EU for BNP. Patents are pending for BNP in the US, China, Russia, India, Brazil and the EU. Patents for BNF technology are pending in the US, China, the EU, Japan, India and Brazil. A US patent was granted in April 2013 for the FlatPack packaging technology, to which NanoLogix has an exclusive license. The FlatPack technology has been pivotal to the sales of filled Petri plates by the company, with extraordinary increases in shelf life, durability of product during shipping, and numerous other advantages over all competitors’ similar products. We have exhibited our BNF and BNP and licensed FlatPack Petri technologies at multiple events: the American Society for Microbiology (ASM) BioDefense and Emerging Diseases Meeting and the Food Safety Summit, both in Washington, D.C., and at the ASM Annual Meeting in San Francisco

Marketing
In 2013, NanoLogix contracted with a team of independent marketing specialists to promote the Company’s products to key opinion leaders (KOLs) and executives in multiple health, industrial, pharmaceutical and food sectors. The marketing team is composed of current or former directors and managers of two national and international pharmaceutical corporations. This alliance continues the transition of the Company from a primary focus on research and development to one of production and marketing. There will be a continued science emphasis upon product Quality Assurance and Quality Control and also water quality test development with the US EPA. This new focus is resulting in a reallocation of resources with a heavy emphasis upon increased high level marketing on multiple fronts.

Financial Matters
As of 1 April 2013, the company has 122,679,679 shares outstanding of an authorized limit of 200,000,000 shares. Our current monthly operations costs are approximately $42,000. That amount includes the costs of NanoLogix-funded studies, other tests of our products by third parties, and new patent applications. NanoLogix is funded by a combination of revenue from increasing sales, loans to the company by its CEO, and a limited number of private placement stock sales, with investors providing funding in exchange for common stock restricted from market sale for one year from date of issuance. The company does not sell shares on the open market. The Company has received a number of inquiries regarding share compensation to Directors and sales of those shares. All Directors are compensated for their contribution to the Company by payment in restricted shares. The Directors are closely involved with the business of the Company, communicate with the CEO on a daily or near-daily basis, and participate in board of director meetings regularly. All Directors have been personally involved in assisting financially with the needs of the Company, both through personal direct investment and also through facilitation of private placement investment from friends, family, colleagues, and associates who approached the Directors. The Directors have been responsible in this way for the overwhelming majority of funds raised to run the company over the past five years, amounting to roughly 92% of funds raised. To date, none of the shares paid to the Directors, including the CEO, have been sold. All of the share certificates issued to the members of the Board of Directors are still classed as restricted shares and can only be sold under strict SEC Rule 144 guidelines. In summation, there has been no realized monetary gain from the shares received as compensation by the Board of Directors --- the shares cannot be used as collateral for loans, nor can they be classed as a liquid asset. The Board of Directors is independent, with the directors employed individually in professions completely unrelated to the business of NanoLogix. Their work as Directors of the Company has been based upon what they believe to be the potential of the Company, not for any immediate capital gain.

In late 2012 and early 2013 Nanologix was approached separately by two multibillion dollar corporations regarding business association, development and product usage. NanoLogix has signed Mutual Confidentiality Agreements with both corporations.

[Gurkensaft]

US EPA and NanoLogix to Extend Agreement to 2015

NanoLogix Inc. (NNLX), an innovator in the accelerated detection, identification and antibiotic sensitivity determination of live bacteria, announces that the US Environmental Protection Agency and NanoLogix have agreed to extend their existing Cooperative Research and Development Agreement (CRADA) for two years, with the new expiration being mid-2015. The CRADA is focused on using NanoLogix-based technologies for development of a comprehensive water quality test kit for testing drinking and source waters in all ten EPA regions.

NanoLogix continues to develop new products and new markets. The company has advanced in a number of areas, including development of new technologies, increasing sales and customer bases, and gaining substantial recognition in published research on NanoLogix products and techniques.

The technology developments at NanoLogix are revolutionary. Improving on existing bacterial diagnostic products and protocols, the Company is achieving success in the market for its Extended-Life Petri dishes and BNP diagnostic kits, both vacuum-packed in gas-charged FlatPacks. The FlatPack technology – exclusively licensed to NanoLogix – represents a major breakthrough in supply-chain management for these products. Customers using FlatPacked Petri dishes achieve significant cost savings and supply chain efficiencies over traditional Petri dishes available from other suppliers. Our products have virtually no breakage in shipment and storage, and have a shelf life far beyond that of traditional filled Petri dishes. Tests of our select nutrient agars demonstrate a usable shelf life, stored at room temperature, of at least one year. This is four times longer than the competition's filled Petri plates that require cold storage. Not requiring refrigeration of select media in filled Petri plates is one of the most important developments in bacterial culture and Petri in decades and provides the potential for use of our products throughout the world, with cold storage, expiration, and fragility no longer the concerns they have been for many decades. Shelf life tests of our filled Petri plates that are kept in cold storage, to date, have shown a usable shelf life of at least two years. All shelf life tests have been conducted by a major independent third-party research laboratory and are continuing.

Customers to date include the US EPA, independent research and hospital laboratories, and defense contractors. NanoLogix products are at present being used on at least six classified Federal government projects, with expanded use expected this year. Those projects are funded by the US Departments of Defense, Homeland Security, and the US Environmental Protection Agency. In the past month, NanoLogix has hired four new production employees to cope with added demand.

NanoLogix has recently signed agreements with companies and distributors in Europe and Asia governing expansion of our business beyond US borders. The Company is currently in talks with other US and foreign-based corporations on use of BNP, BNF and Petri products. In April the Company received a granted patent in Japan for its BNP diagnostic technology. Since that event interests in Japan have approached NanoLogix regarding purchase of BNP for use in TB research.

In the past year we and our collaborators in research at University of Texas Health Science Center at Houston have made significant refinements to our existing technologies and have also developed one additional rapid test. The new test has been named the N-Assay. The N-Assay is a unique ELISA multi-well machine-readable assay that provides results for bacteria identification and antibiotic sensitivity in less than one hour with high sensitivity and specificity. Indications are that the N-Assay will provide rapid results for any bacteria for which an antibody exists. We at NanoLogix and the researchers using the N-Assay are very excited at this new development. The N-Assay is projected to provide a premier platform for Point-of–Care rapid diagnostics. N-Assay patent filings were made in 2013. It is projected that the N-Assay will be more suitable for use in some developed areas than our BNF identification technology, with the BNF useful in areas or regions that are less developed.

The Company exhibited at three professional conferences this year --- The American Society for Microbiology (ASM) BioDefense and Emerging Diseases Research meeting in Washington, DC in February, the Food Safety Summit in Baltimore, and the ASM Annual Meeting in Denver, both in May. At all of these meetings there was strong interest in our products, with sales and promise of sales as a result. At the Denver ASM meeting, the general and specific interest was far beyond any the Company has experienced at any of the consecutive ASM meetings attended since 2008.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity

[bluesrock]

Bitte schön am Boden bleiben, Täubchen

[Gurkensaft]

State of Ohio International Trade Assistance Center at YSU Assists NanoLogix with Foreign Distribution Agreements

NanoLogix Inc., Jan 27, 2014 12:05 AM

HUBBARD, Ohio--(BUSINESS WIRE)--

NanoLogix Inc. (NNLX), an innovator in the rapid detection, identification and determination of antibiotic resistance and sensitivity of live bacteria, announces that the State of Ohio Department of Economic Development’s International Trade Assistance Center (ITAC) based at Youngstown State University (YSU) is providing support to Hubbard Ohio-based NanoLogix Inc. for international distribution of NanoLogix products by Nasaem Al-Jazira, a Saudi Arabian Trading and Distribution Company.

NanoLogix, a biotechnology company, manufactures technologies for uniquely fast detection and identification of bacteria and other microorganisms. Nasaem Al-Jazira, Inc. is headquartered in Riyadh, Kingdom of Saudi Arabia. The distribution agreement was signed January 9, 2014 in Hubbard, Ohio with the CEO’s of both NanoLogix and Nasaem Al-Jazira present and assisted by Mr. Mousa Kassis of ITAC. The agreement was then submitted to the US Department of State and the Embassy of the Kingdom of Saudi Arabia in Washington DC for further approval. The agreement received those approvals the week of Jan 20-24 and has been sent to Saudi Arabia for further processing by the appropriate Saudi Arabian Ministries prior to the beginning of product export to the region. Further information on ITAC and NanoLogix was released in a YSU News Brief: http://www.ysunews.com/ysu-international-trade-assistance-ce…

NanoLogix will distribute their products through Nasaem Al-Jazira in the Gulf Cooperation Council (GCC) area over a 5-year period. The GCC is comprised of Saudi Arabia, Kuwait, Bahrain, Oman, Qatar, and the United Arab Emirates. In a conservative estimate from a Saudi Arabian and GCC marketing expert based in Switzerland, the first year of sales for NanoLogix is projected to total $900,000 from this contract. The agreement provides the opportunity for expansion of the geographic area upon achievement of sales targets. NanoLogix projects the agreement will result in the hiring of additional production workers by summer 2014 with the ramp up in sales.

NanoLogix currently has business relationships in nine countries on four continents. ITAC is working with NanoLogix, Inc. as the company continues to increase business ties with companies in Thailand, Singapore, and Europe. ITAC will assist with further distribution agreements projected for signing with those companies and other companies in 2014.

ITAC is an extension of the Ohio Small Business Development Center at YSU and the Ohio Development Services Agency. Mousa Kassis, ITAC advisor, assists companies with focusing their efforts on increasing export sales and employment, as well as assisting companies in 13 counties. The counties extend from Ashtabula (North) to Tuscarawas and Muskingum (South).

[bluesrock]

Hi,

Sie zuckt, aber ohne Substanz. Leider!

Grüße
Bluesrock

[bluesrock]

Hi,

aber vielleicht zuckts und zappelts ein letztes Mal in diesen Regionen?

Handelsabkommen mit Al-Jazira und weiteres läßt hoffen!

Offensichtlich macht man Fortschritte im Vertrieb. D.h. man ist tatsächlich in der Lage ein markreifes Produkt herzustellen und Nachfrage zu bedienen.

Falls die Gerüchte stimmen, dass man einen ersten Lebensmittelhersteller in OHIO als Kunden gewinnen konnte, bin ich äußert positiv.

Gerade in den USA gab es in der Vergangenheit verschiedene Lebensmittelskandale mit Todesfällen. Sorry, aber hier ist einfach Bedarf und man bzw. NNLX hat wohl ein passendes Produkt.

Grüße
Bluesrock

[Gurkensaft]

Ich bin gerade ebenfalls vorsichtig optimistisch.

Auch in dem kürzlich veröffentlichten Artikel wurden ermunternde Neuigkeiten dargelegt.

http://businessjournaldaily.com/company-news/new-biotechnolo…

Diese müssen sich jetzt nur in Umsatz niederschlagen.

[bluesrock]

Hi Gurke,

wir sind nicht die einzigen. Sollte das der Boden sein gehts bei entsprechenden News steil gen Norden :-)

Schau mer mal - vielleicht ist 2014 ja der Wendepunkt

Grüße
Bluesrock

[Gurkensaft]

http://www.tribtoday.com/page/content.detail/id/601426/Bug-h…

Research going on quietly inside a nondescript Hubbard building is setting a new worldwide standard for the speed in which infectious disease can be diagnosed or dangerous microorganisms like tuberculosis, anthrax or group B streptococcus can be detected.

The developing rapid detection process means quicker diagnosis, quicker treatment and, in many cases, a new way of thinking, especially for the population of third-world countries, said Bret Barnhizer, chief executive officer of Nanologix.

"That's a big deal. That's a huge deal. No one in the history of the world has ever been able to do it this fast," Barnhizer said during a recent interview and tour of the facility.

Other than the simple sign above the door of a building tucked in a picturesque historical setting along North Main Street, most passersby likely have little knowledge of the impact being made by research and development inside.

In addition to the medical field, the company tests and manufactures products used by homeland security and U.S. military for fast detection of microorganisms like anthrax or plague and in the food and beverage industry to detect the presence of bacteria like salmonella or E.coli.

"Salmonella results took many days, then seven days. Now it's under an hour," Barnhizer said. That allows producers to get quick results and ship the products to market faster, translating to a huge dollar savings.

While the company has been in existence for about two decades, it's only in recent years under Barnhizer's direction that Nanologix has turned its focus to rapid detection methods.

Other than serving as a medic during two tours of duty in the Vietnam War and then providing medical aid to Vietnamese civilians, Barnhizer said he had little knowledge of microorganism detection. And after working 25 years in the oil and gas industry, his involvement in the biotechnology company came as a new adventure.

The Mahoning County native had traveled the world, most recently living in Europe before returning to the area to invest in the company that had been operating out of a physician's office in Sharon, Pa. Seeing the growth potential, Barnhizer said he eventually took over as CEO in 2007.

Since then, one of the company's biggest successes includes perfecting technology to speed the detection of TB from more than 21 days previously to now as quick as 90 minutes. Cholera, plague and anthrax, which traditionally took a day or two to detect in a culture, now can be detected in less than an hour, according to literature provided by the company.

Tests performed on all pregnant women worldwide for group B streptococcus, that previously had taken two to three days for results, now can be obtained in less than an hour.

Despite the speed, Nanologix research and development scientist Michelle Durkin is proud of the accuracy.

"We thought we were getting false positives, but we found we were actually picking up other strains of group B strep that other major labs weren't detecting before," Durkin said.

The company also has turned its focus on faster detection of TB, a disease that kills more than a million people a year worldwide. With quicker results, Barnhizer hopes residents of third-world countries, who often don't rate personal health as important as residents of countries like the U.S., will be able to monitor improving health during lengthy antibiotic treatments in a close-to-real-time manner.

"This ability could provide major assistance in the ongoing campaign to combat the scourge of tuberculosis," Barnhizer said, noting his desire to work with the World Health Organization to eradicate TB.

When Nanologix's customers request products they can use to test for various bacteria in the field, Durkin purchases the bacteria from suppliers and uses it to run tests inside the lab.

"We test the product to make sure it works like it is supposed to with all the bacteria," she said.

After that, the challenge becomes safe shipping.

"The goal is to fit it into a kit," Durkin said.

Achieving that goal has been simplified recently with the creation of the "flat-pack," specialized vacuum-sealed packaging invented and patented by Barnhizer. It enables Nanologix to easily preserve, ship and store kits of petri dishes prepared inside the Hubbard laboratory.

And while the company is small - about 12 employees - its developing rapid detection niche is triggering growth. In December the company announced it had struck an exclusive deal with a Saudi Arabian company to distribute NanoLogix products in the Arabian Gulf region. Nanologix also is in negotiations with groups and companies in Europe, Asia and Africa about additional distribution outlets and manufacturing options.

Barnhizer now is planning to add a sales team by the end of summer to help market the products.

"We are small, but ideally, we wont be," Barnhizer said. "We are small, but we are growing."

[bluesrock]

Jetzt hebt sie ab....

[bluesrock]

http://www.businesswire.com/news/home/20141014005326/en/Nano…

[bluesrock]

Hi,
Wir haben Ende 2015 - mit der Meldung von Gestern geht es einen weiteren Schritt in Richtung Kommerzialisierung und Vermarktung. Wenn die Anpassung passt kann noch was ganz großes aus little Nanologix werden.

Bin wieder dabei :-)

HUBBARD, OH--(Marketwired - Dec 21, 2015) - NanoLogix, Inc. (OTC PINK: NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world's three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.

NanoLogix was contacted by the company in February of 2015 and

Grüße
Bluesrock

[south-west]

Diagnostiktechnologie vor Comeback mit ultraschnellem Covid-19 Test

Rockt!

Diagnostiktest unter 1 Stunde. Und ein Entwicklungsveteraen vom Batelle-Institut neu an Bord. Die Zukunft beginnt für Nanologix

http://nanologix.com/downloads/Nanonews-05-03-2020.pdf

[south-west]

Neue Webseite :-)

https://nanologix.com/